Search Results
Your search for ,USE matches 11256 pages
Showing 7001 - 7050ECCO 2017: Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA). Together, stomach and esophageal...
Phase III Trial Finds First-Line Ceritinib Improves PFS vs Platinum-Based Chemotherapy in ALK-Rearranged NSCLC
In a phase III trial (ASCEND-4) reported in The Lancet, Soria et al found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in first-line treatment of advanced ALK-rearranged non–small cell lung cancer (NSCLC). Ceritinib is a next-generation selective...
Postmenopausal Normal-Weight Women With Poor Metabolic Health May Have Higher Risk for Colorectal Cancer
Few studies have explored the association between metabolic phenotype and colorectal cancer incidence in normal-weight individuals. Now, a study comparing the risk of colorectal cancer in normal-weight postmenopausal women with a metabolically unhealthy phenotype vs those with a metabolically...
Immunotherapy 2.0 Named Advance of the Year in ASCO's Report
A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Released today, Clinical Cancer Advances 2017: ASCO's Annual Report on Progress Against Cancer...
Benefits of Multiparametric Magnetic Resonance Imaging in Clinically Significant Prostate Cancer
In the UK PROMIS study reported in The Lancet, Ahmed et al found that use of multiparametric magnetic resonance imaging (MP-MRI) might reduce the need for transrectal ultrasound (TRUS)-guided prostate biopsy and may improve detection of clinically significant prostate cancer. Study Details In the ...
SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers
People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20% of...
Philip E. Bourne, PhD, Leaves NIH, Accepts Position at University of Virginia
On January 6, Francis S. Collins, MD, PhD, Director, National Institutes of Health (NIH), issued the following statement: It is with truly mixed emotions that I announce the departure of Philip E. Bourne, PhD, who will be leaving his post as NIH’s first Associate Director for Data Science to...
Esophagoscopy by the High-Low Method
Endoscopic examination of the intestinal tract remains a prime diagnostic tool for positive identification of cancers. Endoscopic instruments also aid in the retrieval of tissue for biopsy, providing a more accurate diagnosis and help in the staging of tumors. This is a photograph of the pioneer...
What Have We Got to Lose?
Tuesday morning was the regular time for the departmental meeting—an opportunity to discuss cases, troubleshoot, debrief, and expedite the necessary allied health referrals. As usual, patient cases were being discussed in alphabetical order of the attending oncologist. We were already three...
Rucaparib in Previously Treated BRCA Mutation–Associated Ovarian Cancer
On December 19, 2016, rucaparib (Rubraca) was granted accelerated approval for the treatment of patients with deleterious BRCA mutation–associated (germline or somatic) advanced ovarian cancer who have received two or more prior chemotherapy regimens.1,2 The U.S. Food and Drug Administration (FDA) ...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Technically, vitamin D is a secosteroid hormone, not a vitamin. Increasing evidence indicates that vitamin D exerts effects beyond calcium homeostasis. Importantly, for example, higher serum vitamin D levels are associated with better cancer outcomes, including survival.1-3 The protective effects...
FDA Approves Extended-Release Morphine Product Formulated With Abuse-Deterrent Properties
On January 9, the U.S. Food and Drug Administration (FDA) approved morphine sulfate extended-release tablets with abuse-deterrent properties (Arymo ER), a C-II drug for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative...
Telemedicine: Transforming Health Care One Computer at a Time
Telehealth is the delivery of health care remotely via telecommunication tools. Its aim is to increase access to care, especially for patients with chronic diseases such as cancer and for populations for whom care is not always available. With the growing availability of broadband and portable...
New President of the Skin Cancer Foundation Emphasizes Public Education to Reduce Skin Cancer Incidence and Deaths
The statistics on the rising rates of skin cancer are alarming. According to the Skin Cancer Foundation, each year over 5.4 million cases of nonmelanoma skin cancer are treated in more than 3.3 million people, and an additional 76,380 people are diagnosed with the deadliest form of skin cancer,...
Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?
Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not responded to corticosteroids, but this may be about to change. Ibrutinib (Imbruvica) achieved...
ASCO Launches JCO Clinical Cancer Informatics
JCO Clinical Care Informatics (JCO CCI) will be the first ASCO journal devoted to applications of biomedical informatics to cancer care. Debra Patt, MD, MPH, MBA, the Editor-in-Chief of JCO CCI, understands how important biomedical informatics research is to the oncology field. Dr. Patt coauthored ...
ASCO, AMP, and CAP Issue New Joint Guidelines to Standardize Interpretation and Reporting of Sequence Variants in Cancer
On December 16, a set of joint guidelines developed by ASCO, the Association for Molecular Pathology (AMP), and the College of American Pathologists (CAP) on standardizing the interpretation and reporting of sequence variants in cancer was published online, ahead of the January print issue of The...
Paul Sondel, MD, PhD, Receives 2017 SITC Memorial Lectureship Award
Pediatric oncologist Paul Sondel, MD, PhD, of the University of Wisconsin Carbone Cancer Center, has been awarded a top prize in the field of cancer immunology. The Society for Immunotherapy of Cancer (SITC) announced that Dr. Sondel has received the group’s top award—the Richard V. Smalley, MD,...
Radiation Therapy for Glioblastoma: What Is New and What Is Missing in the ASCO-Endorsed ASTRO Guidelines
An ASCO Special Article in the Journal of Clinical Oncology by Sulman et al,1 reviewed in this issue of The ASCO Post, issued ASCO’s endorsement of the American Society for Radiation Oncology (ASTRO) guidelines on radiation therapy for adult patients diagnosed with glioblastoma. It is a positive...
Moffitt Cancer Center Names Robert Wenham, MD, MS, FACOG, FACS, Gynecologic Oncology Program Chair
Moffitt Cancer Center has appointed Robert Wenham, MD, MS, FACOG, FACS, as the new Gynecologic Oncology Program Chair. Dr. Wenham has served as the Interim Chair over the past several months. He was recruited to Moffitt in 2004, after completing his fellowship in gynecologic oncology at the Duke...
Optimizing Access to Fertility Preservation Options
Ensuring that people with cancer understand how cancer treatment could affect their fertility and what options are available for preserving fertility were widely recognized as top priorities by attendees of the 2016 Oncofertility Conference in Chicago. As detailed at the conference, means of...
Managing Breast Cancer in a Pregnant Patient
“One of the most challenging oncologic situations that I face as a clinician is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center, Ann Arbor, told the more than 250...
Brentuximab Vedotin Plus Nivolumab Highly Active in Relapsed Classical Hodgkin Lymphoma
Response rates of 90% to 100% were achieved in early studies evaluating the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma. The findings were presented at the 2016 American Society of Hematology (ASH) Annual Meeting &...
Expert Point of View: Sara Hurvitz, MD; Mothaffar Rimawi, MD; and Carlos L. Arteaga, MD
Sara Hurvitz, MD, Director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, commented that in the United States, a bone mineral density test can help identify candidates for bone-modifying agents. “We look at women who are going on...
Breast Cancer Experts Question New Recommendations for 21-Gene Recurrence Score Assay
At the 2016 San Antonio Breast Cancer Symposium, a group of breast cancer experts made a case for using the 21-gene Oncotype DX Breast Recurrence Score Assay in node-positive patients, despite ASCO’s latest recommendations to restrict it to node-negative estrogen receptor–positive patients. The...
Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer Symposium....
Expert Point of View: Howard A. “Skip” Burris, MD
Howard A. “Skip” Burris, MD, President of Clinical Operations and Chief Medical Officer at Sarah Cannon Research Institute, Nashville, commented on the poster presentation for The ASCO Post. He said the results “fit the whole paradigm” that is desired for triple-negative breast cancer, which is to ...
What Precisely Is Precision Oncology—and Will It Work?
We know from chaos theory that even if you had a perfect model of the world, you’d need infinite precision in order to predict future events. —Nassim Nicholas Taleb The term “precision oncology” is used to describe diverse strategies in cancer medicine ranging from the use of targeted therapies...
Oncology Drug Approvals in 2016
In 2016, the Office of Hematology and Oncology Products of the U.S. Food and Drug Administration (FDA) approved a number of new molecular entities, indications, and tests. The most notable were drug approvals in disease areas such as non–small cell lung cancer, myeloma, head and neck cancer, and...
Institute for Clinical Immuno-Oncology White Paper Highlights the Challenges, Progress, and Priorities in Immunotherapy
While momentum around immunotherapies for cancer continues to build, the high cost of these therapies places them at the center of debate about how best to define and measure value in cancer care. As these therapies are increasingly integrated into practice, all stakeholders—providers,...
Tucatinib Shows Clinical Benefit in Phase I Trial in HER2-Positive Breast Cancer
Phase I clinical trial data published by Moulder-Thompson et al in Clinical Cancer Research reported that the investigational anticancer agent tucatinib (formerly ONT-380) showed 'notable activity' in the treatment of HER2-positive breast cancer with . The 50 women treated had disease...
2017 GI Cancers Symposium: PET Scans Can Inform and Improve Treatment for Patients With Esophageal Cancer
Findings from a federally funded clinical trial—CALGB 80803 (Alliance)—point to a new way to improve the outlook for patients with esophageal cancer: using positron-emission tomography (PET) scans to assess tumor response to initial chemotherapy may allow doctors to tailor further...
Most Federal Exchange Plans Under Affordable Care Act Do Not Contain NCI-Designated Cancer Center
In a study reported in the Journal of Clinical Oncology, Kehl et al found that most federal exchange networks under the Affordable Care Act contain a Commission on Cancer–accredited hospital, but less than half contain a National Cancer Institute (NCI)-designated cancer center. Study Details ...
Fear of Diagnostic Low-Dose Radiation Exposure May Be Overstated, Experts Assert
In an article published by Siegel et al in The Journal of Nuclear Medicine, researchers assert that exposure to medical radiation does not increase a person’s risk of getting cancer. The long-held belief that even low doses of radiation, such as those received in diagnostic imaging, increase...
FDA Approves Morphine Sulfate Extended-Release Tablets Formulated With Abuse-Deterrent Properties
On January 9, the U.S. Food and Drug Administration (FDA) approved morphine sulfate extended-release tablets formulated with abuse-deterrent properties (Arymo ER) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative...
Has the Affordable Care Act Reduced Socioeconomic Disparities in Cancer Screening?
Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially for individuals of lower socioeconomic status. A new study published by Cooper et al in Cancer looked at how the Affordable Care Act (ACA), which eliminated such out-of-pocket...
No Increased Risk of Skeletal Events in Patients With Bone Metastases Taking Zoledronic Acid
A new study published in JAMA reported that patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma who used zoledronic acid every 12 weeks compared with every 4 weeks did not have in an increased risk of skeletal events over 2 years. In this study, Andrew L....
Patients With Non–Small Cell Lung Cancer May Benefit From Delayed Adjuvant Chemotherapy
A new Yale study suggested that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to 4 months after surgery, according to the researchers. The study was published by Salazar et al in JAMA Oncology. Each year, more people die of lung cancer than of...
Results of International Cross-Sectional Survey Reveal Gaps in Primary and Secondary Skin Cancer Prevention, Perceptions, and Knowledge
A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographic disparities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need to...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update of a 2012 ASCO provisional clinical...
ACCC 2016 Survey Finds Cancer Drug Costs Remain the Most Critical Challenge to Care
As more cost pressures are placed on the health-care system, and the transition to value-based care gains momentum, the Association of Community Cancer Centers’ (ACCC) 7th annual Trends in Cancer Programs survey revealed critical challenges and emerging trends in U.S. cancer programs. The...
Genome-Based Model for Adjusting Radiotherapy Dose Shows Promise
In a retrospective cohort–based study reported in The Lancet Oncology, Scott et al found that individual patient genomic-adjusted radiation dose was associated with outcomes across different cancer types. Study Details In the study, gene-expression–based radiation-sensitivity index...
Customer Response to Personal Genomic Testing for Cancer Risk
In a study reported in the Journal of Clinical Oncology, Gray et al found that most people receiving cancer-related data through direct-to-consumer personal genomic testing tended not to change health or screening behaviors when an elevated risk was identified. The study involved baseline and...
Use of Genetic Testing to Identify Patients With Breast Cancer at High Risk for Venous Thromboembolism
Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not recommended ...
Study Suggests No Evidence for Screening Mammography Cutoff Age
An analysis of data from nearly 6 million screening mammograms found no evidence for a clear cutoff age to stop breast cancer screening. Screening mammography among women aged 75 years was associated with higher cancer detection and lower recall rates than among younger women in the study. These...
Exploring Practical Strategies for Cancer Care in Low-Resource Settings
One of the featured “Big Debates” at the 2016 World Cancer Congress in Paris addressed this question: Are scarce resources best applied to prevention rather than treatment? Many experts do not see prevention vs treatment in such stark terms or even as a realistic scenario. It’s a false dichotomy,...
Co-occurrence of Cancer and Cognitive Impairment in Older Adults
The prevalence of both cancer and cognitive impairment increases with age.1-3 Based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare studies, it is estimated that 3% to 7% of patients with cancer aged ≥ 65 also suffer from dementia, although the true prevalence of dementia in this...
The Best of SIO
The following five abstracts were chosen as the best submitted studies presented at this year’s International Conference of the Society for Integrative Oncology (SIO). They represent a diverse group of integrative therapies and interventions in the care of patients with cancer, including an...
Advancing the Global Impact of Integrative Oncology
The 13th International Conference of the Society of Integrative Oncology (SIO) held in Miami, Florida, in November, drew its largest audience yet, with nearly 400 clinicians, researchers, patients, and patient advocates in integrative oncology care from 25 countries in attendance with large...
Genomic Landscape of Metastatic Breast Cancer Differs From That of Primary Breast Cancer
Researchers working on whole-exome and transciptome sequencing of endocrine-resistant estrogen receptor–positive metastatic breast cancer have shown that the mutational landscape differs from that of estrogen receptor–positive primary breast cancer, and these differences have the potential to...
